Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acumen Pharmaceuticals Inc (NQ: ABOS )

2.350 +0.100 (+4.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acumen Pharmaceuticals Inc

< Previous 1 2 Next >
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193 
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.